Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

J. N. Ingle, S. J. Green, D. L. Ahmann, H. J. Long, J. H. Edmonson, J. Rubin, M. N. Chang, E. T. Creagan

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43%) and 25 of 51 TAM, AG and HC patients (49%). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12%) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.

Original languageEnglish (US)
Pages (from-to)958-964
Number of pages7
JournalJournal of Clinical Oncology
Volume4
Issue number6
StatePublished - 1986

Fingerprint

Aminoglutethimide
Tamoxifen
Hydrocortisone
Breast Neoplasms
Therapeutics
Disease Progression
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ingle, J. N., Green, S. J., Ahmann, D. L., Long, H. J., Edmonson, J. H., Rubin, J., ... Creagan, E. T. (1986). Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. Journal of Clinical Oncology, 4(6), 958-964.

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. / Ingle, J. N.; Green, S. J.; Ahmann, D. L.; Long, H. J.; Edmonson, J. H.; Rubin, J.; Chang, M. N.; Creagan, E. T.

In: Journal of Clinical Oncology, Vol. 4, No. 6, 1986, p. 958-964.

Research output: Contribution to journalArticle

Ingle, JN, Green, SJ, Ahmann, DL, Long, HJ, Edmonson, JH, Rubin, J, Chang, MN & Creagan, ET 1986, 'Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer', Journal of Clinical Oncology, vol. 4, no. 6, pp. 958-964.
Ingle, J. N. ; Green, S. J. ; Ahmann, D. L. ; Long, H. J. ; Edmonson, J. H. ; Rubin, J. ; Chang, M. N. ; Creagan, E. T. / Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 6. pp. 958-964.
@article{45c5390cac4f4bd69e090321afbc35f4,
title = "Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer",
abstract = "A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43{\%}) and 25 of 51 TAM, AG and HC patients (49{\%}). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12{\%}) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.",
author = "Ingle, {J. N.} and Green, {S. J.} and Ahmann, {D. L.} and Long, {H. J.} and Edmonson, {J. H.} and J. Rubin and Chang, {M. N.} and Creagan, {E. T.}",
year = "1986",
language = "English (US)",
volume = "4",
pages = "958--964",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

AU - Ingle, J. N.

AU - Green, S. J.

AU - Ahmann, D. L.

AU - Long, H. J.

AU - Edmonson, J. H.

AU - Rubin, J.

AU - Chang, M. N.

AU - Creagan, E. T.

PY - 1986

Y1 - 1986

N2 - A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43%) and 25 of 51 TAM, AG and HC patients (49%). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12%) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.

AB - A randomized clinical trial was performed to compare the efficacy of tamoxifen (TAM) alone with that of TAM plus aminoglutethimide (AG) and hydrocortisone (HC). Patients failing TAM could receive AG and HC. Objective responses to therapy were seen in 21 of 49 TAM patients (43%) and 25 of 51 TAM, AG and HC patients (49%). Time to disease progression and survival distributions were not significantly different between the treatment arms. Toxicity was greater for patients treated with TAM, AG, and HC and the trial was discontinued early for this reason. Twenty-four patients received AG and HC after TAM therapy and three (12%) achieved a response. We conclude that the combination of TAM, AG, and HC is not recommended over TAM alone because toxicity appears to outweigh any potential therapeutic advantage.

UR - http://www.scopus.com/inward/record.url?scp=0022544986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022544986&partnerID=8YFLogxK

M3 - Article

C2 - 3519885

AN - SCOPUS:0022544986

VL - 4

SP - 958

EP - 964

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -